INTRODUCTION
============

Reliable secondary use of Electronic Health Record (EHR) data is fundamental to learning healthcare systems;[@ooz020-B1]^,^[@ooz020-B2] Promising research endeavors such as comparative effectiveness research[@ooz020-B3]^,^[@ooz020-B4] and precision medicine[@ooz020-B5] heavily rely on identifying correct patients. Correspondingly, patient Diagnosis (DX) data is often a starting point of cohort selection for secondary use.[@ooz020-B8]^,^[@ooz020-B9] Thus, the accurate and precise assignment of structured DX data within EHRs is crucial to ensure reliable research outcomes.[@ooz020-B10] DX code recording has well-known limitations[@ooz020-B11] and decades of research have revealed poor DX code data quality through alarmingly high inaccuracy rates.[@ooz020-B10]^,^[@ooz020-B12]^,^[@ooz020-B13] Despite some improvements on error rates over time (i.e., ICD code inaccuracy rates went from 20--70% in the 1970s to 20% in 1980s), their reliability remains questioned.[@ooz020-B3]^,^[@ooz020-B14] The complex nature of clinical knowledge, variability of clinical workflows, and clinical data being generated for care and billing rather than research[@ooz020-B3]^,^[@ooz020-B15]^,^[@ooz020-B16] have led to development of workaround methods[@ooz020-B17] including natural language processing (NLP) to access clinical notes, EHR phenotyping, and post hoc data quality assessments.[@ooz020-B19] Though these methods are helpful in unlocking existing poor-quality data, they do not tackle the problem of producing more reliable datasets for future research. Other fields have successfully leveraged data quality improvement techniques ensuring reliable data recording at the source[@ooz020-B17]^,^[@ooz020-B21]^,^[@ooz020-B25]^,^[@ooz020-B26] but this is generally seen as unfit for the clinical setting due to its complex sociotechnical nature.[@ooz020-B27]^,^[@ooz020-B28] These secondary use challenges are compounded by EHR systems that provide multiple descriptions for each individual DX code.[@ooz020-B29] Though they are intended to facilitate DX code search in practice, the large number of options complicates selecting the most appropriate textual descriptions, increasing the potential erratic DX data recording.[@ooz020-B30]

Although this is a healthcare-wide issue, the problem is compounded and most evident in electronic oncology patient charts.[@ooz020-B31]^,^[@ooz020-B32] On one hand, cancer care is team-based and requires multiple specialties and units (e.g., scheduling, encounters, billing, diagnostic imaging, surgical procedures, radiotherapy, etc.); This creates more opportunities for discordant DX recording. EHR systems rarely address this condition, failing to support consistent DX code recording across workflows and making DX logging burdensome to oncologists.[@ooz020-B33] On the other hand, current versions of standard DX codes and descriptions are not designed to support secondary use of clinical data.[@ooz020-B3] For example, ICD-10 codes C71.\* correspond to a malignant neoplasm of the brain DX. These codes allow encoding of the neoplasm site (e.g., C71.1 represents a malignant neoplasm of the frontal lobe) but, as opposed to ICD-O-3 codes,[@ooz020-B36] they are not designed to provide information on neoplasm type (e.g., *IDH* mutant glioma, *IDH* wild type glioma, glioblastoma, etc.) crucial patient classification to treatment selection. However, EHR vendor-provided DX descriptions may include neoplasm type information but vary widely in precision. This complicates structured DX data recording,[@ooz020-B30] leading to unreliable recording of these DX descriptions preventing their use in patient cohort development for reliable reuse of clinical data.

Our previous work shows that recoding presumably-accurate diagnostic information (i.e., a cancer patient's biopsy \[BX\]) does not increase subsequent data accuracy and does not reduce DX data variability in EHRs of patients treated for brain neoplasms in a system with multiple textual DX descriptions per DX.[@ooz020-B30]^,^[@ooz020-B37] These findings led us to believe that DX data quality may be affected by the EHR data entry system design and clinical workflows, given that DX data is directly dictated by the BX report in such clinical context. These results also imply that, in the current state of EHR systems design, accurate information does not propagate to populate the rest of the patient's chart. This is likely to be the case for other segments of the EHR and other clinical specialties. However, we analyzed data for a limited pilot cohort of patients from a single clinical subspecialty. In this study, we *tested our initial result's internal validity* of in a larger cohort, hypothesizing that (I) the effect found in the pilot cohort will be preserved in the larger cohort. We also *explored their external validity* by replicating the study in two other patient cohorts for other oncology subspecialties. Given that DX logging across specialties can vary widely, (this is often noted qualitatively[@ooz020-B38] but has yet to be shown explicitly and quantitatively in the field) we also hypothesized that (II) DX recording patterns will differ across subspecialties. We tested our hypotheses on EHR data from patients diagnosed with brain, lung and pancreatic neoplasms (i.e., ICD-10 diagnosis codes, C71.\*, C34.\*, and C25.\*). We selected these diseases for their large number of textual diagnosis descriptions (i.e., their potential for precise structured DX recording) for a limited list of specific diagnosis codes, the availability of a clinician-generated patient cohort and each patient chart containing a definitive histopathology report stating the most precise DX description possible. We present descriptive statistics and statistical modeling results that show the existence of seemingly stable DX recording patents that appear to be disease and subspecialty-specific. This analysis contributes to our current understanding of DX logging practices and their differences across workflows and subspecialties by providing concrete, quantitative and explicit evidence of such differences and logging practice variability. Our findings provide further insights to enable reliable reuse of DX data reuse but also lay the groundwork for the development of adaptive clinical data entry support interventions. The resulting understanding aims to unlock new avenues to overcome current challenges introduced by existing EHR systems designs providing multiple DX description per DX code. We also seek to introduce the idea of using such structured textual DX descriptions as a potential source of semi-structured data for cohort selection. Particular care needs to be given to care team and subspecialty differences when making secondary use of clinical data, carrying out clinical data quality assessments and developing patient cohorts using DX data. Our work also suggests support must be provided to clinicians to ensure systematic recording of structured clinical data across subspecialties to enhance clinical data quality and ensure the reliability of secondary analyses of clinical data as a step towards building learning healthcare systems.

METHODS
=======

We extracted diagnoses codes for encounter, problem list, and orders with their corresponding diagnosis descriptions, encounter dates, and ICD-10 codes from the Wake Forest Baptist Medical Center's Translational Data Warehouse. This database contains all raw data generated during patient care. Our dataset also included surgical pathology reports and relevant covariates such as BX date. We used a clinician-generated gold standard to identify patients treated for each neoplasm. We employed a combination of statistical and NLP tools to quantify DX logging variability in each subspecialty. We built binomial regressions to predict whether DX data appeared before or after the BX based on the number of distinct DX descriptions and DX description "particularity" (i.e., how much semantic information is included in the textual description to differentiate each DX). A "descriptive specificity" or "particularity" score was calculated by extracting clinical concepts from DX descriptions using NLP tools and assigning scores for tumor histology description precision and tumor location.[@ooz020-B30] Last, we investigated particularity score entropy (i.e., a measure of diversity representing the average amount of information in scores sequences), as a measure of variability in DX descriptions chosen by users before and after the BX. Our study was approved by Wake Forest University School of Medicine's Institutional Review Board before any data extraction or analysis.

Our patient lists were distilled from the charts of patients treated for brain, lung, and pancreatic neoplasms. Patients were pre-selected during previous clinician-initiated chart reviews. A comprehensive medical record review was performed by two physicians for each patient. The primary post-operative diagnosis was determined based on review of pathology report and progress notes. All treating clinicians were available for consultation when needed. Discrepancies between the two reviewers were resolved by an independent specialist. Our final datasets spanned between January 1st, 2016 to June 1st, 2018. This time frame ensured ICD coding version consistency (i.e., to include DXs after October 2015; ICD-10 implementation date). Each dataset contained 21,136 DX observations for 120 brain neoplasm patients, 119,411 DX observations for 256 lung neoplasm patients and 30,020 DX observations for 34 pancreatic neoplasm patients.

We augmented our dataset with a DX "particularity" score[@ooz020-B30] based on NLP-extracted[@ooz020-B39] NCI thesaurus terminology[@ooz020-B40] concepts from textual DX code descriptions. We define particularity as the ability of a diagnosis description to pinpoint a diagnosis with the most specific concepts available in a relevant controlled clinical vocabulary and provide the most additional descriptive elements (e.g., tumor site) to classify patients. For this study, we used a particularity scoring system to quantify particularity based on both concept specificity and additional descriptive elements. EHRs provide clinicians with these clinically-relevant labels to facilitate DX code selection (i.e., each DX description was linked to an ICD-10 code; C71.\*, C34.\*, or C25.\* codes in our dataset). For example, "Oligodendroglioma of frontal lobe" was attached to C71.1, generically named "Malignant neoplasm of frontal lobe" in the ICD-10 taxonomy. Scores depended on (1) the "descriptiveness" (i.e., relative concept "depth" in the NCI thesaurus structure)[@ooz020-B40] of the extracted neoplastic process concepts (e.g., glioma is a general neoplastic process description with relative score of "0," glioblastoma scored "1" as a direct child of the glioma concept in the NCI thesaurus) and (2) whether we found a concept describing the neoplasm's anatomical site. For example, particularity score in brain DX ranged from 0 for "Malignant neoplasm of brain, unspecified location" to 3 for "Oligodendroglioma of frontal lobe". We also calculated DX description sequence and DX particularity score entropy as a measure of DX description diversity and DX particularity score variation using the 'entropy' R package to foster reproducibility.[@ooz020-B41] This R package automatically estimates empirical entropy form observation sequences (i.e., DX or Particularity score entropy) using a maximum likelihood estimation algorithm. In the rest of this paper we refer to "DX Entropy" as the entropy of DX sequences and "Score Entropy" as the entropy of particularity score sequences before or after the BX.

We built binomial regressions using R's generalized linear model[@ooz020-B42] and mixed models (lme4) packages.[@ooz020-B43] We selected binomial regressions because our dichotomous main outcome variable 'After BX' that indicated whether a DX was recorded before or after the BX. Our original hypotheses[@ooz020-B30] aimed to explore differences before and after the BX. We evaluated differences in number of distinct DX with a binomial regression model predicting the "After DX" variable based on the number of distinct DX descriptions. The same kind of model was used to estimate differences in DX sequences and particularity score entropy[@ooz020-B44] values. We built a binomial mixed regression model to evaluate the relationship between DX particularity scores before and after BX. We chose a mixed model to account for each DX score as an independent test and account for intra-subject correlation by attributing random intercepts to each patient. We evaluated the quantitative effect difference across subspecialties by aggregating all three datasets and building the same models controlling for the type of disease diagnosed. We tested for model improvement through covariate inclusion. We included variables such as number of days before or after the BX each DX was recorded, the provider recording the DX and the department (i.e., care units involved in patient treatment such as oncology, surgery, and neurology) where the DX was recorded. We also tested for variable interactions in all models with more than one variable. Summary statistics such as mean, median, and extreme values were employed to screen the data for outliers, missing values and erroneous input. Dates were also reviewed for potential errors such as values being outside the study's time window. Statistical significance was set at *p *= 0.05 for all models and adjustments for multiple comparison were made using *R*'s *p*.adjust function[@ooz020-B45] using Holm's correction method.[@ooz020-B46] We refer to the odds ratios as OR and adjusted p values as adj-*p*.

Multiple software tools were used to carry out this analysis. Data extraction and preprocessing was done using a DataGrip software client (version 2017.2.2, JetBrains s.r.o., Prague, Czech Republic). Visual exploration and exploratory descriptive statistics were done using Tableau (version 10.2.4, Tableau Software, Inc., Seattle, WA). All statistical analyses and data manipulation such as data scrubbing and reshaping were done in R version 3.4.1[@ooz020-B30] and RStudio (version 1.1.383, RStudio, Inc., Boston, MA).

RESULTS
=======

Our final datasets contained 21,136 encounter, problem list and order DX observations out of which 2,690 were primary encounter DX for 120 brain neoplasm patients, 119,411 DX observations for 256 lung neoplasm patients, and 30,020 DX observations for 34 pancreatic neoplasm patients ([Table 1](#ooz020-T1){ref-type="table"}). Primary encounter brain DX contained 68 distinct DX descriptions corresponding to 8 ICD-10 codes, logged by 144 distinct providers from 47 distinct hospital departments. The average number of days from the BX was 170 ± 189 days. The average particularity score was 0.96 ± 0.71. These statistics were mostly driven by the post-BX data, as expected due to additional treatment data generation. Pre-BX data contained 200 DX observations for 30 patients with 31 distinct DX descriptions corresponding to 4 ICD-10 codes. The number of providers and departments also dipped to 31 and 12 correspondingly. This is expected due to the reduced clinical evidence to make accurate a precise DX before the BX is available as well as the lower number of visits before the treatment plan is defined. Days from BX and Particularity score kept comparable standard deviations, while showing lower averages before the BX as expected (i.e., −137 ± 139 and 200 ± 164 for days and 0.78 ± 0.70 and 0.97 ± 0.71 for pre and post BX particularity). The full datasets containing encounter, problem list, and order DX observations 71,209 and 29 distinct DX descriptions for brain, lung, and pancreas correspondingly. These corresponded to 8, 22, and 10 ICD-10 codes, logged by 268, 592, and 29 distinct providers from 111, 193, and 99 distinct hospital departments. The average number of days from the BX was 189 ± 186, 215 ± 254, and 189 ± 299 days, correspondingly. The average particularity score was 1.01 ± 0.68, 3.76 ± 3.34 and 8.24 ± 9.7, correspondingly, hinting at fundamental differences across DX logging patterns across subspecialties.

###### 

Descriptive statistics for primary brain DX and all DX data for brain, lung, and pancreas. These descriptive statistics show differences in DX logging volumes, DX description variability, and DX particularity

                                             Primary brain DX   Encounter, problem list, and order DX                                          
  ------------------------------------------ ------------------ --------------------------------------- ------------ ------------ ------------ -----------
  Distinct patients                          120                30                                      117          120          256          34
  Number of DX records                       2,690              200                                     2,490        21,136       119,411      30,020
  Distinct ICD-10 codes                      8                  4                                       8            8            22           10
  Distinct DX descriptions                   68                 28                                      64           71           209          29
  Distinct providers                         144                31                                      137          268          592          305
  Distinct hospital department               47                 12                                      46           111          193          99
  Days from BX  (Mean ±Std.Dev.)             170 ±189           137 ±139                                200 ±164     189 ±186     215 ±254     189 ±299
  DX particularity Score  (Mean ±Std.Dev.)   0.96 ±0.71         0.78 ±0.70                              0.97 ±0.71   1.01 ±0.68   3.76 ±3.34   8.24 ±9.7

Our full brain neoplasm DX dataset yielded similar effect sizes the initial results[@ooz020-B30] for both the primary encounter DX and multi-workflow DX data ([Table 2](#ooz020-T2){ref-type="table"} and [Supplementary appendix](#sup1){ref-type="supplementary-material"}[Table A1](#ooz020-T1){ref-type="table"}). We provide full regression tables in [Supplementary Appendix](#sup1){ref-type="supplementary-material"} A. For the primary encounter DX dataset, we found that adding an additional distinct DX would make a DX sequence 77.7% more likely to appear after the BX (adj-*P* = 0.02). Max days from BX was a significant covariate but had a very small effect (OR = 1.004, adj-*P* = 0.021). For all brain DX, we found that adding a new distinct DX would make a DX sequence 2.2 times more likely to happen after the BX (adj-*P* \< 0.0001). Only problem list DX were statistically different from other DX types (adj-*P* \< 0.0001) ([Supplementary Table A1](#sup1){ref-type="supplementary-material"}). Particularity score increments of a unit would make a DX 40% more likely to appear after the DX (adj-*P* \< 0.0001); both order and problem list DX were different in this regard (adj-*p* = 0.02 and adj-*P* = 0.003). Entropy regressions showed that higher DX sequence entropy made a sequence more likely to happen after the BX (OR = 3.79, adj-*P* = 0.004) and that higher particularity score also made the sequence more likely to be post-BX (OR = 7.89, adj-*P* \< 0.0001). Neither regression showed any statistically significant covariate relationship after *P*-adjustment nor any difference across DX types.

###### 

Brain DX variability regressions. Post-BX data shows more distinct DX, higher particularity scores but also higher entropy in DX and particularity score sequences

  Model                   Term                    Odds ratio (exp(ß))   Confidence interval (95%)   *P*-value   Adjusted *P*-value   
  ----------------------- ----------------------- --------------------- --------------------------- ----------- -------------------- ----------
  Distinct primary DX     Distinct DX number      1.777                 0.180                       1.023       0.007                0.020
  Max days from BX        1.004                   0.001                 0.007                       0.013       0.021                
  Distinct DX             Distinct DX number      2.219                 0.573                       1.046       \<0.0001             \<0.001
  Particularity           Particularity score     1.402                 0.228                       0.450       \<0.0001             \<0.0001
  DX entropy              DX entropy              3.788                 0.586                       2.110       0.001                0.004
  Particularity entropy   Particularity entropy   7.981                 1.080                       3.130       \<0.0001             \<0.0001

We found qualitatively different results for both our lung and pancreatic neoplasm DX datasets ([Table 3](#ooz020-T3){ref-type="table"}, [Supplementary Table A2 and A3](#sup1){ref-type="supplementary-material"}). Lung neoplasm revealed a smaller effect in the number of distinct DX (OR = 1.50, adj-*P* \< 0.0001) and the same difference in problem list DX (adj-*P* = 0.0001). The effect of the particularity score was also much smaller (OR = 1.085, adj-*P* \< 0.0001) with the same differences for order and problem list DX (adj-*P* \< 0.0001). However, higher DX sequence and particularity score entropy made a sequence more likely to happen *before* the BX (OR = 0.51, adj-*P* = 0.001, and OR = 0.47, adj-*P* = 0.017). This means that, *contrary to brain neoplasm DX, lung neoplasm DX were less erratic after the BX*. Neither of these regressions revealed differences across DX types. None of the lung regressions showed significant covariate relationships or interactions ([Supplementary Table A2](#sup1){ref-type="supplementary-material"}). Pancreatic neoplasm DX regressions ([Table 3 and Supplementary Table A3](#ooz020-T3){ref-type="table"}) revealed no statistical relationship between the number of distinct DX (OR = 1.36, adj-*P* = 1) nor differences across DX types (adj-*P* = 1). The effect of the particularity score was opposite (OR = 0.92, adj-*P* \< 0.0001) with DX type differences for order and non-primary encounter DX (adj-*P* = 0.025 and adj-*P* = 0.033) rather than problem list DX (adj-*P* = 0.931). This means that for pancreatic neoplasm DX, a more particular DX description is 9% less likely to appear after the BX. However, higher DX sequence entropy made a sequence more likely to happen before the BX, revealing more consistent logging after the BX (OR = 0.32, adj-*P* = 0.046). *In contrast with brain neoplasm DX and just like lung neoplasm, DX sequences were less erratic after the BX*. Particularity score entropy showed no statistically significant relationship (adj-*P* = 1). Both regressions showed a significant relationship between Post-BX and the number of days from BX but with a very small effect (OR = 1.003, adj-*P* \< 0.0001 for both regressions). Neither regression revealed differences across DX types. No interaction term was found significant in the pancreatic neoplasm regressions.

###### 

Lung and pancreatic neoplasm regressions. The effects found for these subspecialties are qualitatively different from those found for brain neoplasm. Both subspecialties seem to present lower entropy values after the BX, in contrast with brain neoplasm DX. The effect of particularity seems different for all three subspecialties

  Sub-specialty           Model & term         Odds ratio (exp(ß))   Confidence interval (95%)   *P*-value   Adjusted *P*-value   
  ----------------------- -------------------- --------------------- --------------------------- ----------- -------------------- ----------
  Lung                    Distinct DX number   1.500                 0.293                       0.524       \<0.0001             \<0.0001
  Particularity score     1.085                0.069                 0.094                       \<0.0001    \<0.0001             
  DX entropy              0.508                −1.044                −0.315                      0.0002      0.001                
  Particularity entropy   0.473                −1.267                −0.237                      0.004       0.017                
  Pancreas                Distinct DX number   1.363                 −0.145                      0.810       0.197                1
  Particularity score     0.915                −0.109                −0.067                      \<0.0001    \<0.0001             
  DX entropy              0.324                −2.077                −0.205                      0.017       0.046                
  Particularity entropy   0.976                −1.130                1.073                       0.965       1.000                

We also found quantitative differences across subspecialty datasets ([Table 4](#ooz020-T4){ref-type="table"}). We found statistically significant differences between the number of distinct DX in brain neoplasm DX data and lung neoplasm (OR = 0.54, adj-*P* \< 0.0001) as well as pancreatic neoplasm (OR = 0.58, adj-*P* = 0.009). We found similar differences for particularity scores with significantly lower odds ratios that hinted at much higher particularity in lung and pancreatic neoplasm data (OR = 0.198, adj-*P* = 0.015 and OR = 0.099, adj-*P* = 0.015). Entropy values were also significantly different in all cases except for pancreas particularity score entropy (adj-*P* = 0.080). The entropy models revealed statistically significant differences hinting at lower entropy in the lung and pancreas datasets as compared to the brain dataset (OR = 0.53, adj-*P* \< 0.0001, and OR = 0.56, adj-*P* = 0.014 for DX sequence entropy, for lung and pancreas correspondingly; OR = 0.54, adj-*P* \< 0.0001 for lung particularity score entropy). For both entropy regressions, we found a statistically significant relationship with max days from BX with a low effect size (OR = 1.005, adj-*P* \< 0.0001 in both cases). No other covariates were significantly correlated. No interactions were found significant.

###### 

Effect comparison regressions. Both lung and pancreatic neoplasm data seem to have quantitatively different effects from brain neoplasm DX in terms of distinct DX number, particularity scores, and entropy

  Model                   Term                    Odds ratio (exp(ß))   Confidence interval (95%)   *P*-value   Adjusted *P*-value   
  ----------------------- ----------------------- --------------------- --------------------------- ----------- -------------------- ----------
  Distinct DX             Distinct DX number      1.457                 0.292                       0.464       \<0.0001             \<0.0001
  Brain                   1                       --                    --                          --          --                   
  Lung                    0.538                   −0.911                −0.333                      \<0.0001    \<0.0001             
  Pancreas                0.580                   −0.919                −0.171                      0.004       0.009                
  Particularity           Particularity score     1.041                 0.030                       0.050       \<0.0001             \<0.0001
  Brain                   1                       --                    --                          --          --                   
  Lung                    0.198                   −2.912                −0.374                      0.012       0.015                
  Pancreas                0.099                   −4.043                −0.625                      0.007       0.015                
  DX Entropy              DX entropy              0.904                 −0.415                      0.212       0.525                1
  Max days from BX        1.005                   0.004                 0.005                       \<0.0001    \<0.0001             
  Brain                   1                       --                    --                          --          --                   
  Lung                    0.529                   −0.944                −0.334                      \<0.0001    \<0.0001             
  Pancreas                0.561                   −0.980                −0.178                      0.005       0.014                
  Particularity Entropy   Particularity entropy   1.581                 0.031                       0.888       0.036                0.080
  Max days from BX        1.005                   0.004                 0.005                       \<0.0001    \<0.0001             
  Brain                   1                       --                    --                          --          --                   
  Lung                    0.542                   −0.923                −0.308                      \<0.0001    \<0.0001             
  Pancreas                0.628                   −0.877                −0.054                      0.027       0.080                

In summary, we confirmed the internal validity of our initial results for brain neoplasm cases (i.e., larger number of distinct DX, higher particularity scores, and higher entropy after the BX); odds ratio values also close. Replicating the analysis in lung and pancreatic neoplasm patient charts, we found DX logging pattern differences across subspecialties. Lung and pancreas DX both seemed to have lower DX sequence entropy and therefore more consistent DX recording after the BX contrarily to brain neoplasm DX. Particularity odds ratios were different for all three datasets; differences between datasets were statistically significant in most cases.

DISCUSSION
==========

We used statistical regressions to evaluate structured DX data differences before and after BX reports are recorded in EHR records for oncology patients ([Figure 1](#ooz020-F1){ref-type="fig"}). We found that DX entry patterns were similar for two different brain cancer cohorts but qualitatively and quantitatively different from cohorts of patients treated for lung and pancreatic cancer. These results provide quantitative evidence that suggests that clinicians establish a stable EHR interaction mechanism for entering structured DX data, that this workflow remains consistent over time and that it may vary by subspecialty or disease-type. This implies that interaction design for data entry should be carefully considered by EHR vendors and clinical interface designers to support the accurate and precise data entry. The subspecialty differences have important implications as efforts to improve and optimize DX data entry may thus be different based on the disease area. This hints at the need for disease-process-specific data entry support, which justifies the use of advanced data-driven methods such as machine learning to achieve personalized support for the entry of accurate clinical data. Data quality assessment research and method development efforts should also take these data production differences into account when evaluating a repurposed dataset's fitness for purpose.[@ooz020-B47]

![Odds ratio and statistical difference findings summary.](ooz020f1){#ooz020-F1}

Our study extends the existing literature by exploring aspects beyond the predominant DX code recording accuracy analyses.[@ooz020-B1]^,^[@ooz020-B32]^,^[@ooz020-B52] We showed the limited impact of a DX source of truth (i.e., the BX report) in the EHR on subsequent DX recording, confirming our previous findings for a pilot cohort of patients treated for brain neoplasms.[@ooz020-B30] Though previous studies have explored multiple EHR segments to assess data quality,[@ooz020-B11]^,^[@ooz020-B13]^,^[@ooz020-B31]^,^[@ooz020-B32]^,^[@ooz020-B38]^,^[@ooz020-B53] they often focus on providing accuracy measure results to warn secondary users of clinical data against direct analysis of repurposed clinical data. Our study takes this a step further by exploring patterns in a segment of the EHR where no variability should exist due to the availability of a BX that provides a source of accurate information. This was the main reason for choosing oncological charts. We were also unable to find similar analyses on repurposed EHR data quality focusing specifically on oncological DX data. Thus, our study focuses on breaking new ground and opening new avenues of research from the vantage point of oncological patient charts into all segments of EHR databases. It is interesting that we found evidence that DX recording processes may be stable for different disciplines within a common disease state. For example, we collected DX data for specialists in medical oncology, neuro-oncology, radiation oncology, and neurosurgical oncology for patients with primary brain neoplasms. Despite the differences in specialty and training, relatively little variability was observed within this patient cohort likely reflecting the common clinical workflows that are established by clinicians caring for this patient population. In contrast, we observed significant differences between the DX data for this multidisciplinary care team and a similar multidisciplinary lung and pancreatic team. This is congruent with previous accuracy-driven EHR data analyses.[@ooz020-B38] Our findings stress the ties between clinical practice to the resulting data. Secondary analyses of clinical data[@ooz020-B1]^,^[@ooz020-B3]^,^[@ooz020-B54] and data quality assessments[@ooz020-B48]^,^[@ooz020-B50]^,^[@ooz020-B51]^,^[@ooz020-B55]^,^[@ooz020-B56] need to account for such cross-practice differences. Though our analysis was conducted exclusively on oncology EHRs, we used these data as a setup to better understand the impact of clinical data entry.

We also explored the impact of multiple descriptions linked to single diagnostic codes on structured data entry. To our knowledge, only our initial analysis[@ooz020-B30] has explored the effect of such a setup. Finding that clinicians logged more distinct DX descriptions after the BX in two out of three subspecialties confirms our initial hypothesis that multiple DX description per code may increase DX entry variability even after the DX is known through the BX report. This observation also raises questions about how the currently available DX code lists within the EHR drive clinician practice. Anecdotal discussions with clinicians in these specialty areas suggest that DX data tables available in the EHR may drive some of the clinical practices observed in this study. Subsequent investigation is currently being conducted to better understand this finding. This, in turn, confirms that data entry and the resulting intrinsic data quality[@ooz020-B49]^,^[@ooz020-B57] are likely to be impacted by EHR interface design and demanding clinical workflows.[@ooz020-B33]^,^[@ooz020-B58]^,^[@ooz020-B59] This corroborates that clinical data is a tangential product of clinical care and is affected by clinical processes such as billing,[@ooz020-B34]^,^[@ooz020-B60] rather than the ideal raw material for clinical research.[@ooz020-B3] Much current research aiming to support secondary analysis of clinical data aims to develop methods for data quality assessment and data curation in isolation from the clinical practice.[@ooz020-B4]^,^[@ooz020-B48]^,^[@ooz020-B55]^,^[@ooz020-B56]^,^[@ooz020-B61] Yet, our results suggest that the quality of extracted clinical data is directly linked to the process that produced them; They also suggest that data quality can be improved by altering the process. For example, integrating specialty-dependent diagnosis lists (e.g., ICD-O) into the EHR system could be beneficial to improve data entry, quality, and concordance. The data entry process could also be revised. For example, ICD-O diagnoses could be presented first for oncology patients or could be prompted when a pathology report indicates a cancer diagnosis in the EHR. It is crucial that future development in this area should take into account such cross-process differences to ensure the reliable secondary use of clinical data.[@ooz020-B65]

Our analysis presents three main limitations. First, we focused our study on a limited number of clinical conditions (i.e., brain, lung, and pancreatic neoplasms). However, we were able to evaluate differences across subspecialties quantitatively and qualitatively finding different DX logging profiles for each subspecialty. Our data and analyses provided adequate evidence to evaluate our hypotheses and test the internal and external validity of our initial results. We will further extend this analysis to other subspecialties to better understand DX logging differences across clinical workflows; We also expand to specialties outside oncology. A related limitation was not accounting for comorbidities. However, the informatics-driven nature of our analysis, along with the relatively large number of patients for each dataset and large effect sizes suggest that the phenomenon is driven by clinical practice and workflows rather than the patient's clinical profile. Comorbidity effects will also be explored in future work. Second, our particularity scoring has yet to be validated with a gold standard. However, our DX particularity scoring was simple, transparent, and systematic enough to be considered a repeatable feature extraction process.[@ooz020-B66]^,^[@ooz020-B67] The score was based on summing a point for anatomical location concepts found and neoplastic process concept's precision based on its depth in the NCI Thesaurus classification,[@ooz020-B40] a well-known and standardized classification of clinical concepts. The validation for this method is planned in our future work. Finally, we only evaluated DX description variability (number of distinct DX), average particularity before and after BX and the entropy of these two values rather than DX accuracy. Although it would have been ideal to evaluate the accuracy of each DX entry as a measure of intrinsic data quality, we defined our variables to measure variability in a context where no variability should exist because the DX is known in the EHR through the BX report. In this context, DX variation is a reliable proxy for inaccuracy that our regressions were able to uncover.

Future work will be divided into three segments: further analyses to confirm DX logging patterns differences across subspecialties, the exploration of root causes through qualitative research and the development of workflow-adaptive interventions to increase DX data quality and support systematic DX logging across specialties. First, we will explore differences across other specialties and validate our particularity scoring system. We will also analyze temporal patterns to better understand data entry dynamics. Then, we will carry out qualitative research such as interviews and focus groups to explore the underlying causes DX logging differences across subspecialties. We will also carry out additional quantitative analyses to explore potential factors influencing data entry processes and contributing to DX data entry variability. Finally, we will employ informatics methods to develop clinician-adaptive interventions to support systematic, accurate and concordant DX recording leveraging fragmented data across EHRs. We will also explore the idea of centralized DX entry to assess whether such intervention increases DX concordance across the EHR.

CONCLUSION
==========

Our analysis provides quantitative evidence showing that disease-specific DX entry patterns exist and are established differently by clinical subspecialty. Secondary users of clinical data should consider these differences when designing analyses and performing data quality assessments. Standardized interventions able to accommodate these differences and support systematic, accurate, precise, and concordant DX entry across subspecialties must be developed and implemented to increase the reliability of structured DX data and enable reliable secondary analyses of clinical data. Overcoming such challenges may support the improvement of overall clinical data quality,[@ooz020-B48]^,^[@ooz020-B49]^,^[@ooz020-B57] reliability of secondary analyses of clinical data[@ooz020-B1] and the building of the learning system.[@ooz020-B31]^,^[@ooz020-B68]^,^[@ooz020-B69]
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